Biohaven (BHVN) Stock Forecast & Price Target

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$38.99

-3.17 (-7.52%)

(As of 04/19/2024 ET)

Biohaven Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$52.00
33.37% Upside

High Forecast	$63.00
Average Forecast	$52.00
Low Forecast	$28.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$52.00	$49.67	$35.38	$38.39
Predicted Upside	33.37% Upside	26.95% Upside	35.53% Upside	18.49% Upside

Get Biohaven Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

BHVN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BHVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biohaven Stock vs. The Competition

Type	Biohaven	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.68	2.49
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	33.06% Upside	967.12% Upside	11.77% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
4/9/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$61.00	+18.01%
3/4/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$50.00 ➝ $63.00	+27.17%
3/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$35.00 ➝ $55.00	+14.25%
2/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$32.00 ➝ $56.00	+15.97%
2/6/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$59.00	+25.19%
12/8/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$58.00	+75.70%
11/15/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$29.00 ➝ $36.00	+18.69%
6/5/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$24.00 ➝ $28.00	+29.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 08:36 PM ET.

BHVN Price Target - Frequently Asked Questions

What is Biohaven's consensus rating and price target?: According to the issued ratings of 8 analysts in the last year, the consensus rating for Biohaven stock is Buy based on the current 8 buy ratings for BHVN. The average twelve-month price prediction for Biohaven is $52.00 with a high price target of $63.00 and a low price target of $28.00. Learn more on BHVN's analyst rating history.
Do Wall Street analysts like Biohaven more than its competitors?: Analysts like Biohaven more than other Medical companies. The consensus rating for Biohaven is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how BHVN compares to other companies.
Does Biohaven's stock price have much upside?: According to analysts, Biohaven's stock has a predicted upside of 22.27% based on their 12-month stock forecasts.

What analysts cover Biohaven?: Biohaven has been rated by Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Royal Bank of Canada, TD Cowen, and UBS Group in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NYSE:BHVN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biohaven (BHVN) Stock Forecast & Price Target

Biohaven Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

BHVN Analyst Ratings By Month

BHVN Price Targets by Month

Biohaven Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

BHVN Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info